Get started
Author

Rosario Di Maggio

Observed names: R. Di Maggio, Rosario DI Maggio, Rosario di Maggio
Observed institutions: National Institutes of Health, Ospedale Vincenzo Cervello, National Heart, Lung, and Blood Institute, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo, Fondazione Franco e Piera Cutino, University of Palermo
ORCID: 0000-0001-9568-9688
Observed ORCID: 0000-0001-9568-9688
OpenAlex ID: A5086307993
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial
2022 · Farid Boulad, Aurelio Maggio, et al. · Nature Medicine · 59
The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?
2016 · Angela Vitrano, Giuseppina Calvaruso, et al. · British Journal of Haematology · 58
The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major
2017 · Rosario Di Maggio, Aurelio Maggio · British Journal of Haematology · 54
PDF
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5‐year long‐term I talian multicenter randomized clinical trial
2015 · Giuseppina Calvaruso, Angela Vitrano, et al. · American Journal of Hematology · 49
PDF
Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients
2012 · Aurelio Maggio, Angela Vitrano, et al. · American Journal of Hematology · 35
PDF
Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021
2022 · Raffaella Origa, Barbara Gianesin, et al. · Cancer · 29
PDF
Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial
2014 · Giusi Calvaruso, Angela Vitrano, et al. · Blood Cells Molecules and Diseases · 20
Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study
2025 · Barbara Gianesin, Frédéric B. Piel, et al. · Haematologica · 18
PDF
Luspatercept for Transfusion‐Dependent Beta‐Thalassemia: Real‐World Experience in a Large Cohort of Patients From Italy
2025 · Raffaella Origa, Barbara Gianesin, et al. · American Journal of Hematology · 15
Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
2018 · Rosario Di Maggio, Matthew Hsieh, et al. · International Journal of Molecular Sciences · 13
PDF
Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice
2025 · Valeria Maria Pinto, Rosanna Cima, et al. · Journal of Clinical Medicine · 12
Impact of lifetime anaemia and iron control on outcomes in β‐thalassaemia: Data from the longitudinal de‐ LIGHT study
2025 · Khaled M. Musallam, Angela Vitrano, et al. · British Journal of Haematology · 11
β-Thalassemia heterozygote state detrimentally affects health expectation
2018 · Luciano Graffeo, Angela Vitrano, et al. · European Journal of Internal Medicine · 11
Real‐life experience with liver iron concentration R 2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET
2016 · Angela Vitrano, Giuseppina Calvaruso, et al. · European Journal Of Haematology · 11
Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET
2017 · Angela Vitrano, Massimiliano Sacco, et al. · European Journal Of Haematology · 9
Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures
2016 · Serena Sclafani, Alice Pecoraro, et al. · Hematology Reports · 9
PDF
Co‐heredity of silent CAP + 1570 T>C ( HBB :c*96T>C) defect and severe β‐thal mutation: a cause of mild β‐thalassemia intermedia
2015 · M. Vinciguerra, C. Passarello, et al. · International Journal of Laboratory Hematology · 9
Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy
2022 · Giovanna Graziadei, Lucia De Franceschi, et al. · Frontiers in Medicine · 8
PDF
Long‐term sequential deferiprone and deferasirox therapy in transfusion‐dependent thalassaemia patients: a prospective clinical trial
2019 · Angela Vitrano, Giovan Battista Ruffo, et al. · British Journal of Haematology · 6
PDF
Mesenchymal Fetal Stem Cells (FMSC) from Amniotic Fluid (AF): Expansion and Phenotypic Characterization
2015 · Maria Concetta Renda, Emanuela Fecarotta, et al. · Blood · 6
Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia
2025 · Khaled M. Musallam, Angela Vitrano, et al. · American Journal of Hematology · 4
PDF
Erratum to: Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study
2025 · Barbara Gianesin, Frédéric B. Piel, et al. · Haematologica · 4
PDF
Overcoming the Cost Barrier for Thalassemia Innovative Treatments
2023 · Angela Vitrano, Rita Barone, et al. · Blood · 4
Response to Alpha-Interferon Treatment of the Congenital Dyserythropoietic Anemia type I in Two Sicilian Beta Thalassemia Carriers
2016 · V. Agrigento, R. Barone, et al. · Indian Journal of Hematology and Blood Transfusion · 4
Hematopoietic Stem Cell Mobilization for Gene Therapy: The Combination of G-CSF+Plerixafor in Patients with Beta-Thalassemia Major Provides High Yields of CD34+ Cells with Primitive Signatures
2015 · Elena Baiamonte, Rita Barone, et al. · Blood · 4
Works count: 56
Citation count: 490
H-index: 11
I10-index: 14
Year
Topic
Type